We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
+$23.6M
Cap. Flow
+$98.4M
Cap. Flow %
3.98%
Top 10 Hldgs %
53.52%
Holding
129
New
25
Increased
23
Reduced
34
Closed
26

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$125M
2
Z icon
Zillow
Z
+$35.8M
3
UBER icon
Uber
UBER
+$21.2M
4
CYCN icon
Cyclerion Therapeutics
CYCN
+$19.3M
5
HOOK
HOOKIPA Pharma
HOOK
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$48.8M
2
IFRX icon
InflaRx
IFRX
+$31.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$11M
4
WVE icon
Wave Life Sciences
WVE
+$9.71M
5
VICI icon
VICI Properties
VICI
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 63.4%
2 Consumer Discretionary 15.74%
3 Technology 4.81%
4 Communication Services 1.88%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
51
DELISTED
Alder Biopharmaceuticals
ALDR
$10M 0.4%
850,000
+350,000
+70% +$4.24M
MORF
52
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.91M 0.4%
+500,000
New +$9.46M
ADPT icon
53
Adaptive Biotechnologies
ADPT
$3.59B
$9.66M 0.39%
+200,000
New +$8.86M
TBIO
54
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$9.47M 0.38%
750,000
+150,000
+25% +$1.58M
YMAB
55
DELISTED
Y-mAbs Therapeutics
YMAB
$9.15M 0.37%
+400,000
New +$9.19M
STNE icon
56
StoneCo
STNE
$2.69B
$8.87M 0.36%
+300,000
New +$8.83M
REPL icon
57
Replimune Group
REPL
$405M
$8.8M 0.36%
600,000
– –
DNLI icon
58
Denali Therapeutics
DNLI
$3.79B
$8.3M 0.34%
400,000
– –
TPTX
59
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$8.14M 0.33%
+200,000
New +$7.13M
KYNB
60
Kyntra Bio
KYNB
$28.2M
$8.13M 0.33%
7,200
-800
-10% -$876K
AUTL
61
Autolus Therapeutics
AUTL
$381M
$8.05M 0.33%
500,000
+50,000
+11% +$1.12M
TGTX icon
62
TG Therapeutics
TGTX
$8.32B
$7.79M 0.31%
900,000
+100,000
+13% +$756K
ARQL
63
DELISTED
Arqule Inc
ARQL
$7.71M 0.31%
+700,000
New +$4.87M
HOOK
64
DELISTED
HOOKIPA Pharma
HOOK
$7.64M 0.31%
+113,462
New +$12M
AGEN
65
Agenus
AGEN
$279M
$7.5M 0.3%
127,375
-12,738
-9% -$696K
RGNX icon
66
Regenxbio
RGNX
$617M
$7.45M 0.3%
145,000
-25,000
-15% -$1.25M
MRNA icon
67
CALL
Moderna
MRNA
$22B
$7.32M 0.3%
+500,000
New +$10.7M
TCRR
68
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$7.01M 0.28%
490,000
– –
SLDB icon
69
Solid Biosciences
SLDB
$788M
$6.9M 0.28%
80,000
– –
CRWD icon
70
CrowdStrike
CRWD
$183B
$6.83M 0.28%
+400,000
New +$6.8M
SPRO icon
71
Spero Therapeutics
SPRO
$67.7M
$6.21M 0.25%
540,000
-60,000
-10% -$722K
GRTS
72
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$5.57M 0.23%
500,000
+300,000
+150% +$3.43M
ACIU icon
73
AC Immune
ACIU
$233M
$5.55M 0.22%
1,000,000
– –
STML
74
DELISTED
Stemline Therapeutics, Inc.
STML
$5.51M 0.22%
360,000
-40,000
-10% -$579K
RCKT icon
75
Rocket Pharmaceuticals
RCKT
$336M
$5.4M 0.22%
360,000
-40,000
-10% -$698K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2019 Portfolio in Review

As of Q2 2019, Artal Group held 129 positions worth $2.47B, up 0.96% from $2.45B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Artal Group deployed $98.4M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Avantor: 7,000,000 shares worth $134M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 64% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $8.59M trimmed.

  • Artal Group's largest Q2 2019 buy was Avantor: 7,000,000 shares worth $134M.
  • Artal Group added most to Zillow in Q2 2019, an estimated $35.8M increase.
  • Artal Group's biggest Q2 2019 reduction was Moderna, cutting an estimated $8.59M.
  • Artal Group fully exited Array Biopharma Inc in Q2 2019, selling an estimated $48.8M.
  • Artal Group's ten largest holdings make up 54% of its $2.47B portfolio in Q2 2019.
  • Artal Group opened 25 new positions and closed 26 in Q2 2019.
  • Artal Group's portfolio value rose 0.96% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.